You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Clin-Alert

Journal indexing and metrics

Journal Homepage Submission guidelines

Restricted access

Research article

First published online 2020-5

Reporting on Adverse Clinical Events

Volume 58, Issue 9-10

https://doi.org/10.1177/0069477020924640

Abstract

Keywords

Alirocumab* (123)Amisulpride (125)Amygdalin (129)Antidepressants (134)Aripiprazole (136)Aspirin (126)Benzodiazepines (121)Bromide (132)Cabazitaxel (119)Clozapine (137 138)Gabapentin (138)Imipenem/Cilastatin (139)Milk Thistle (140)Nivolumab (127 130)Nizatidine (120)Omeprazole (135)Opium (141)Oxaliplatin (142)Paliperidone (143)Propofol (122)Rituximab (131)Rosiglitazone (118)Sulfamethoxazole/Trimethoprim (128)Terlipressin (133)Turmeric (124)Vancomycin (117)Warfarin (140)

Get full access to this article

View all access options for this article.

Browse journal

Current issue OnlineFirst All issues

Similar articles

Retricted access

Reporting on Adverse Clinical Events

Retricted access

Reporting on Adverse Clinical Events

Retricted access

Reporting on Adverse Clinical Events

Retricted access

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion